Abstract:BackgroundCardiovascular disease remains a major health care challenge. The knowledge about the underlying mechanisms of the respective vascular disease etiologies has greatly expanded over the last decades. This includes the contribution of microRNAs, endogenous non-coding RNA molecules, known to vastly influence gene expression. In addition, short interference RNA has been established as a mechanism to temporarily affect gene expression. This review discusses challenges relating to the design of a RNA interference therapy strategy for the modulation of vascular disease. Despite advances in medical and surgical therapies, atherosclerosis (ATH), aortic aneurysms (AA) are still associated with high morbidity and mortality. In addition, intimal hyperplasia (IH) remains a leading cause of late vein and prosthetic bypass graft failure. Pathomechanisms of all three entities include activation of endothelial cells (EC) and dedifferentiation of vascular smooth muscle cells (VSMC). RNA interference represents a promising technology that may be utilized to silence genes contributing to ATH, AA or IH. Successful RNAi delivery to the vessel wall faces multiple obstacles. These include the challenge of cell specific, targeted delivery of RNAi, anatomical barriers such as basal membrane, elastic laminae in arterial walls, multiple layers of VSMC, as well as adventitial tissues. Another major decision point is the route of delivery and potential methods of transfection. A plethora of transfection reagents and adjuncts have been described with varying efficacies and side effects. Timing and duration of RNAi therapy as well as target gene choice are further relevant aspects that need to be addressed in a temporo-spatial fashion.ConclusionsWhile multiple preclinical studies reported encouraging results of RNAi delivery to the vascular wall, it remains to be seen if a single target can be sufficient to the achieve clinically desirable changes in the injured vascular wall in humans. It might be necessary to achieve simultaneous and/or sequential silencing of multiple, synergistically acting target genes. Some advances in cell specific RNAi delivery have been made, but a reliable vascular cell specific transfection strategy is still missing. Also, off-target effects of RNAi and unwanted effects of transfection agents on gene expression are challenges to be addressed. Close collaborative efforts between clinicians, geneticists, biologists, and chemical and medical engineers will be needed to provide tailored therapeutics for the various types of vascular diseases.

RNA Therapeutics for the Cardiovascular System

Current RNA strategies in treating cardiovascular diseases

RNA in cardiovascular disease: A new frontier of personalized medicine

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease

Small non-coding RNA therapeutics for cardiovascular disease

RNA-based Therapeutics: an Overview and Prospectus

Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics

Recent Advances and Prospects in RNA Drug Development

Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration

RNA Therapeutics - Research and Clinical Advancements

RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations

Ethical implications of developing RNA-based therapies for cardiovascular disorders

Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives

RNA therapeutics in the clinic

mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration

Current Advances in RNA Therapeutics for Human Diseases

Non-viral Nucleic Acid Therapeutics: Revolutionizing the Landscape of Atherosclerotic Treatment

Innovative developments and emerging technologies in RNA therapeutics

RNA-Binding Proteins: Emerging Therapeutics for Vascular Dysfunction

RNA‐based medicine: from molecular mechanisms to therapy

The Limitless Future of RNA Therapeutics